DNA vaccines for hepatitis
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections pose a significant global public-health problem and are major causes of chronic liver disease. Three to five times more people are living with chronic viral hepatitis infections than with HIV infection. In the U.S., it is estimated that as many as 5.3 million people—about 1 in every 50 people—are living with chronic HBV or HCV infections.
Current therapies are associated with significant side effects. Inovio believes a therapeutic DNA vaccine to treat HBV and/or HCV would offer physicians a powerful tool in the fight against this all-too common infectious disease. Inovio’s strategy is to advance hepatitis synthetic vaccines through multiple collaborations to fund and conduct relevant clinical studies, as shown in the table below.
|Candidate||Vaccine Type||Disease Type||Target Antigens||Collaborator|
|Synthetic multi-antigen DNA vaccine||Hepatitis C virus genotypes 1a and 1b||NS3/4A, NS4B, NS5A||VGX International Inc.|
|ChronVac-C® HCV||DNA vaccine||Hepatitis C virus genotype 1a||NS3/4A||ChronTech Pharma AB|
|HBV||Synthetic multi-antigen DNA vaccine||Hepatitis B||Undisclosed||VGX International Inc.|